WaveMan
WaveMan · Company
NVNO · Envveno Medical Corp
> Search tickers & screens ⌘K
LIVE
← All companies

NVNO enVVeno Medical (NVNO) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001661053
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
3
13F, latest reported quarter

What the filings say about NVNO

Insiders, 180 days
-$1.6K net sold
1 seller · 50% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$123
1 notice

enVVeno Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, enVVeno Medical Corp insiders sold a net $1.6K of stock across 16 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Duhay Francis
Director
SELL
2026-09-14 SECtraded 2026-09-11
11
$123
-28.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (2 buys, 4 sales), the last on Jun 11, 2026.
  • -4.0% median (-4.0% mean) 90-day return after 2 previous buys.
  • The trade is 0.5% of the 2,351 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duhay Francis sold about $123 of NVNO under a 10b5-1 plan on Sep 11, 2026; 3 funds added in the latest 13F quarter.
Duhay Francis
Director
SELL
2026-06-12 SECtraded 2026-06-11
140
$1.4K
-32.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on Mar 12, 2026.
  • -4.0% median (-4.0% mean) 90-day return after 2 previous buys.
  • The trade is 5.9% of the 2,362 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duhay Francis sold about $1.4K of NVNO on Jun 11, 2026; 3 funds added in the latest 13F quarter.
Duhay Francis
Director
SELL
2026-03-13 SECtraded 2026-03-12
140
$1.6K
-37.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Dec 11, 2025.
  • -4.0% median (-4.0% mean) 90-day return after 2 previous buys.
  • The trade is 5.6% of the 2,502 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duhay Francis sold about $1.6K of NVNO on Mar 12, 2026; 3 funds added in the latest 13F quarter.
Duhay Francis
Director
SELL
2025-12-12 SECtraded 2025-12-11
4,900
$1.8K
-38.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Sep 15, 2025.
  • -4.0% median (-4.0% mean) 90-day return after 2 previous buys.
  • The trade is 5.3% of the 92,544 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duhay Francis sold about $1.8K of NVNO on Dec 11, 2025; 3 funds added in the latest 13F quarter.
Duhay Francis
Director
SELL
2025-09-17 SECtraded 2025-09-15
4,900
$4.1K
-79.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 31, 2024.
  • -4.0% median (-4.0% mean) 90-day return after 2 previous buys.
  • The trade is 5.0% of the 97,444 shares held after it.
  • No other insider sold within 30 days.
  • 3 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Duhay Francis sold about $4.1K of NVNO on Sep 15, 2025, the largest insider sale at the company since 2024; 3 funds added in the latest 13F quarter.
16 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 11 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.6K over 180 days
-$123 over 90 days
more than 63% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
3 funds bought in last quarter
below 99% of Medical Devices
Revenue
-83.3% year over year
below 97% of Medical Devices
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
2.0% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 65% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NVNO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-73.4%12M
-74%-49%-25%+0%2025-102025-122026-022026-042026-062026-082026-10 2025-12-11 · Duhay Francis sold $1.8K2026-03-12 · Duhay Francis sold $1.6K2026-06-11 · Duhay Francis sold $1.4K2026-09-11 · Duhay Francis sold $1232026-02-20 · Braeden Lichti filed a 5%+ stake (5.05%)2026-02-20 · Northstrive Fund II LP filed a 5%+ stake (3.07%)2026-02-20 · Northstrive Fund II LP filed a 5%+ stake (3.07%)2026-02-20 · Braeden Lichti filed a 5%+ stake (5.05%)2026-09-11 · Duhay Francis filed to sell $123
Insider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NVNO: institutional holders (13F)

13F holdings, latest reported quarter
KINGDON CAPITAL MANAGEMENT, L.L.C.
36,166 sh
$387.3K
CM Management, LLC
35,714 sh
$382.5K
VANGUARD CAPITAL MANAGEMENT LLC
6,287 sh
$67.4K
JPMORGAN CHASE & CO
5,208 sh
$59.1K
VANGUARD FIDUCIARY TRUST CO
2,184 sh
$23.4K

Congress trades in NVNO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Braeden Lichti
Activist 13D · 2026-02-20
5.05%
Northstrive Fund II LP
Activist 13D · 2026-02-20
3.07%
Northstrive Fund II LP
Activist 13D · 2026-02-20
3.07%
Braeden Lichti
Activist 13D · 2026-02-20
5.05%

NVNO planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Duhay Francis
Filed 2026-09-11
$123

NVNO mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$67.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$67.4K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$6.6K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$9.1K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$9.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.6K sold by insiders over 180 days, 3 funds added last quarter, $123 in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

NVNO financials

Revenue growth
-83.3%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$31.2K
four quarters, 2019-01-01 to 2019-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-58.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-53.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-61.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$20.9M-$23.8M-$25.2M-$24.9M
Net income-$19.5M-$21.8M-$23.5M-$24.7M
EPS (diluted)-33.06-44.53-1.91-2.20
Operating cash flow-$15.6M-$16.8M-$18.9M-$15.6M
Cash$3.1M$1.8M$3.6M$4.6M
SEC XBRL, fiscal years, as known on 2026-10-28

NVNO Stock Sonar score 5/7 axes

Find similar shapesCompare

NVNO ranks highest on risk and compliance (71st percentile) and profitability (31st), and lowest on institutional and government (1st), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
31
Inputs
  • Return on equity-58.5% · 36 pct, sector of 183
  • Return on assets-53.1% · 29 pct, sector of 214
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-61.7% · 28 pct, sector of 188
Growth
3
Inputs
  • Revenue growth, YoY-83.3% · 3 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
31
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1K · 62 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
1
Inputs
  • Funds adding, latest quarter3 · 1 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
71
Inputs
  • Short interest, % of float+2.0% · 68 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.3% · 74 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NVNO filings, in plain words

Are enVVeno Medical insiders buying or selling NVNO?

In the 180 days to 2026-10-28, enVVeno Medical insiders were net sellers, a net $1.6K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of NVNO?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $123 of stock; the latest, by Duhay Francis, was filed 2026-09-11.

Read the full summary

In the 180 days to 2026-10-28, enVVeno Medical insiders were net sellers of NVNO, a net $1.6K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $123 of stock. The latest 5% ownership filing is a 13D by Braeden Lichti, filed 2026-02-20, for 5.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies